Effect of methylprednisolone combined with iguratimod in the treatment of Sj?gren's syndrome
Objective To investigate the effect of methylprednisolone combined with iguratimod in the treatment of Sjögren's syndrome.Methods A total of 84 patients with Sjögren's syndrome were randomly assigned to a control group and a observation group,with 42 patients in each group.Patients in the control group were treated with methylprednisolone combined withhydroxychloroquine sulfate,while those in the observation group were treated with methylprednisolone combined with iguratimod.The clinical effect,the EULAR Sjögren's syndrome patient reported index(ESSPRI),the EULAR Sjögren's syndrome disease activity index(ESSDAI),Schirmeri test,salivary flow rate,serum indicators and the incidence of adverse reactions were compared between the 2 groups.Results The treatment response rate in the observation group(90.48%)was significantly higher than that in the control group(71.43%),P<0.05.After treatment,the ESSPRI scores and ESSDAI scores of the 2 groups decreased,and the observation group had lower scores than the control group(P<0.05).Schirmeri test values and salivary flow rates in the 2 groups increased,and the 2 indicators in the observation group were higher than those in the control group(P<0.05).The levels of interleukin-17(IL-17),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP)and immunoglobulin G(IgG)in the 2 groups decreased,and the levels in the observation group were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion Methylprednisolone combined with iguratimod is effective in the treatment of Sjögren's syndrome,which can significantly relieve clinical symptoms and inflammatory reactions,and improve lymphocytes infiltration,with high safety.
万方数据
维普
